


Cat No. 10-G06

17-AAG

1 mg

17-AAG is a synthetic derivative of geldanamycin and acts as an anti-tumor agent. 17-AAG binds specifically to heat shock protein Hsp90. Hsp90 is a protein chaperone that binds to client proteins. Client proteins include important cancer-relevant targets such as mutated p53, Her2, Bcr-Abl, Raf-1, Akt and others. 17-AAG disrupts the Hsp-900 client protein complexes and leads to the degradation of the client proteins.

TECHNICAL INFORMATION



Other Names: NSC 330507, 17-(Allylamino)-17-demethoxygeldanamycin, 17-Demethoxy-17-(2-propenylamino)geldanamycin

Chemical Formula: C₃₁H₄₃N₃O₈

CAS Number: 75747-14-7

Molecular Weight: 585.69

Purity: >99%

Appearance: purple solid

Solubility: DMSO, ethanol



For research purposes only

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store aliquots at -20°C.

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

PRODUCT USE

Soluble in DMSO at 150mg/ml. Soluble in ethanol at 5mg/ml. Very poorly soluble in water.

REFERENCES

1. Schulte et al. (1998) The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. *Cancer Chemother Pharmacol.* 42 (4):273-9.
2. Kamal et al. (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. *Nature.* 425(6956):407-10.
3. Vasilevskava et al. (2004) Quantitative effects on c-Jun N-terminal protein kinase signaling determine synergistic interaction of cisplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines. *Mol Pharmacol* 65(1):235-43.